Bibliographic analysis of existing evidence for treatment of novel coronavirus pneumonia drugs

Objective: Documentary retrieval and analysis of available evidence of drugs that may be used to treat novel coronavirus pneumonia (corona virus disease-19, COVID-19) to provide evidence-based medical basis for the treatment of the disease. Method: The computer retrieves PubMed, Clinic Trial.gov and the official website of the China Clinical Trials Registration Center to find research on the treatment of COVID-19. The literature screening is conducted independently by two researchers based on the criteria for inclusion and exclusion, and the final classification is summarized and analyzed according to the study drug category. Result: 2 case reports suggest that ridesivir, lopinavir, ritonavir and abidol may be used in COVID-19 treatment; but one small sample retrospective cohort study results suggest that the efficacy of lopinavir and abidol is not clear; in vitro studies, chloroquine and daranavir Severe acute respiratory syndrome coronavirus type 2 (severe Activity of acute respiratory syndrome coronavirus 2, sars-cov-2); the basis for ribavirin and interferon treatment of COVID-19 is primarily derived from the severe acute respiratory syndrome coronavirus (severe acute respiratory syndrome) Coronavirus, Sars-CoV) and the treatment of MERS-CoV (Middle East respiratory syndrome coronavirus, Mers-CoV). Currently, several randomized controlled trials to evaluate the efficacy and safety of the drug treatment COVID-19 are under way. Conclusion: Although the current antiviral treatment of COVID-19 is not supported by high-quality evidence-based medical evidence, several studies have been launched to evaluate the clinical efficacy of TCM and Western medicine treatment programs and will provide high-quality evidence support for COVID-19 treatment.